Also a factor is the unproven nature of its ARCUS gene therapy platform, used in the gene-editing of its allo CAR-Ts and pipeline of in vivo ...
https://www.google.com/url?rct=j&sa=t&url=https://scrip.pharmaintelligence.informa.com/SC146135/Well-Be-First-With-OffTheShelf-CART-Vows-Precision-Biosciences--And-Hopes-To-Win-Over-GeneEditing-Skeptics&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNEaICQyJAT6cb9HKeAV3z3PDAZ0rw
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.